A number of New England tech and life sciences companies had deals to be thankful for this week.
—CloudBees, a startup soon to be headquartered in Boston, raised $4 million in a Series A financing round led by Matrix Partners. Individual investors Marc Fleury and Bob Bickel also backed CloudBees, which is developing a cloud-based platform for Java computing and development.
—Israel- and California-based Mellanox (NASDAQ: [[ticker:MLNX]]) agreed to acquire Chelmsford, MA-based Voltaire (NASDAQ: [[ticker:VOLT]]) for $8.75 per share, or a total equity value of $218 million. Mellanox plans to retain employees and product lines from Voltaire, which makes servers, switches, and software for high-performance and cloud computing environments.
—Heartland Robotics of Cambridge, MA, raised $20 million in Series B financing, led by new investor Highland Capital Partners and joined by Sigma Partners, Charles River Ventures, and Bezos Expeditions. Founded by robotics pioneer Rodney Brooks, the startup isn’t revealing much about its technology, a line of robots designed to make U.S. manufacturing more productive and efficient.
—Aileron Therapeutics, also of Cambridge, inked a deal with The Scripps Research Institute in La Jolla, CA. Terms of the deal—which gives Aileron exclusive rights to Scripps’ “click” chemistry—were not disclosed.
—Mobile app maker FitnessKeeper of Boston closed a $1.1 million financing led by O’Reilly AlphaTech Ventures. Existing investors LaunchCapital, Will Herman, Dave Balter, and Don McLagan also participated in the deal for the startup, whose RunKeeper app allows runners to track their distance, speed, and routes.
—Lebanon, NH-based antibody drug developer Adimab raised $4 million in a Series E funding round at a pre-money valuation of $520 million—double the value of the company in October 2009, when it raised its last round, according to CEO and co-founder Tillman Gerngross. The latest round came entirely from previous backers, including Google Ventures, Borealis Ventures, OrbiMed Advisors, Polaris Venture Partners, and SV Life Sciences.
